Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Alunbrig a New Treatment Option for Lung Cancer in Patients with ALK Mutation

June 2017 Vol 3 No 3

On April 28, 2017, Alunbrig (brigatinib; from Takeda) became the newest drug to be approved by the FDA for the treatment of metastatic non–small-cell lung cancer (NSCLC) in patients with the ALK mutation whose tumor progressed while receiving crizotinib or patients who cannot use crizotinib. Alunbrig is a kinase inhibitor and comes as pills that are taken orally.

The clinical trial that led to this approval investigated 2 doses of Alunbrig—180 mg and 90 mg; overall, 53% of patients who took the 180-mg tablet had a good response compared with 48% of patients who took the 90-mg tablet, but severe side effects were slightly higher with the higher dose. The recommended starting dose of Alunbrig is 90 mg for the first 7 days; if the patient tolerates this dose, it should be increased to 180 mg.

The most common side effects reported with the 180-mg dose were nausea, diarrhea, fatigue, cough, and headache. Serious side effects occurred in 38% of patients taking the 90-mg tablet and in 40% of patients taking the 180-mg tablet. Pneumonia and lung disease were the most serious side effects. In addition, almost 4% of patients who received this new drug died because of a fatal adverse reaction, mainly related to lung problems and infections.

Recommended For You